Tobacco Giants Speak on THR at GFN: Calling for Regulatory Reform Aligned with Scientific Understanding

Jun.26.2025
At the GFN 2025, representatives from the world’s four largest tobacco companies emphasized the need for science-driven harm reduction policies. They urged regulators to move beyond outdated approaches and adopt consumer-focused, evidence-based frameworks to better serve public health goals.

[Reporting from Warsaw — Taco Tuinstra, 2Firsts] The recent Global Forum on Nicotine (GFN) provided a platform to a wide variety of stakeholders. From June 19-21, health advocates, public policy analysts, lawmakers and others convened in Warsaw to advance tobacco harm reduction (THR). 2Firsts has been the official media partner of the Global Forum on Nicotine (GFN) for three consecutive years, delivering in-depth and timely coverage of the event to the global industry audience.

 

While each of the participants offered valuable insights, the success of safer nicotine products will depend largely on the actions of the world’s four largest tobacco companies, which between them account for nearly 70 percent of cigarette volume sales outside China.

 

Given their outsized influence, 2Firsts took special note of the GFN contributions from Philip Morris International, British American Tobacco, Japan Tobacco International and Imperial Brands. Boasting profound expertise and unmatched resources, the views of these companies are key in the transition from deadly cigarettes to less risky smoking alternatives.

 

Describing the scope of the challenge, BAT Global Medical Safety Officer Hugo Tan reminded listeners that there are 1.3 billion smokers worldwide, and that annually 8 million people die prematurely due to smoking-related health complications. By comparison, he noted that the Covid-19 crisis resulted in about 7 million deaths. “If Covid was a pandemic, if it was a public health crisis, then what about the 8 million deaths from smoking?” he asked.

 

To accelerate the progress toward less-risky alternatives, Tan called for better education of healthcare professionals. “Not too long ago, when I was in medical school, we were taught about the harmful effects of smoking, but we learned nothing about the science about alternative nicotine products,” Tann said. “How we teach medical students needs to change.”

 

Tobacco Giants Speak on THR at GFN: Calling for Regulatory Reform Aligned with Scientific Understanding
Summer Hanna (third from left) during a panel discussion evaluating WHO science | Photo: Taco Tuinstra

 

 

Corroding Curiosity

 

In that context, big-company representatives at GFN worried about the growing hostility to THR by leading health bodies. While the World Health Organization’s (WHO) Framework Convention on Tobacco Control (FCTC) lists THR as a fundamental pillar of tobacco control, the officials administrating the treaty increasingly dismiss the concept as an industry ploy to addict a new generation of nicotine users.

 

When the FCTC was drawn up, “the WHO recognized that progress and technology transformation would evolve to change and transform smokers' lives, and that harm reduction strategies would then become the third leg of their approach,” said Summer Hanna, head of scientific regulation at BAT.

 

“Unfortunately, over the last 20 years, we've seen that scientific mindset and curiosity erode. We now have leading jurisdictions of tobacco control—countries like the U.K. or New Zealand—with progressive regulatory frameworks and remarkable declines in the rate of cigarette smoking,” she said. “Meanwhile, the FCTC is still reporting, 20 years later, over 1 billion smokers. To me, that's a failure of creativity and scientific process.”

 

Hanna attributed the resistance to THR in part to the growing disconnect between policymakers and consumers. “I'm not confident how many of the people who are working in [the tobacco control] space actually know any smokers,” she said. “As smoking becomes less of a middle class or upper-class phenomenon, people who sit and learn at institutions do not ever interact with these people in their personal lives. They become an abstract entity. In the same way that the tobacco industry becomes a monolith, the smoker also becomes a monolith in this.”

 

Tobacco Giants Speak on THR at GFN: Calling for Regulatory Reform Aligned with Scientific Understanding
Thomas Nahde | Photo: Taco Tuinstra

 

This divide also makes it easier to vilify the other side. Noting that smoking is a consumer behavior rather than a communicable disease Thomas Nahde, global head of harm reduction and engagement at Imperial Brands, cautioned against framing tobacco control’s mission as a “war.”

 

“A narrative of war on a behavior is misapplied,” Nahde said. “I'm conscious that it's about urgency, but it demonizes smoking and stigmatizes people who smoke. It also substantially limits the options if you're using a narrative of eradication rather than control. We need way more focus on the consumer, to really understand the behavior of people who smoke.”

 

 

The Fight for Flavors

 

One behavior that has attracted widespread attention is consumers’ tendency to buy flavored products. In many jurisdictions, regulators have responded with bans and restrictions, often citing youth appeal as justification. At GFN, various experts reflected on the significance of flavors and the impact of restrictions.

 

Deborah Binks-Moore, chief corporate officer at Imperial Brands, cautioned against the unintended consequences of flavor bans. “In our sector, the big challenge faced by all of us, industry regulators and policy makers, is how do you provide choices that encourage adults to transition away from smoking, while banishing the rogue actors who undermine trust and encourage unintended or youth use,” she said.

 

“In one of our studies, 29% of smokers who switch from tobacco exclusively used fruit flavors, and where we see restrictions on flavors, either through regulatory inertia or legislative bans, we see a proliferation of the illegal, unregulated market. And once the market moves into the hands of criminals, there is a greater risk of unintended [use] or youth use and consumption of harmful products.”

 

She cited the case of Australia, where overregulation has shifted the business from legitimate suppliers to law-evading ones. “There are around 1 million vapers in Australia, and more than 90% of the vapes that those people consume are bought illegally, so a staggering number of law-abiding consumers who want to make a choice to improve their health have effectively become criminals through bad policy, and it's enriching criminal gangs,” said Binks-Moore. “It just is nonsensical.”

 

Piotr Kozarewicz, U.S. senior advisor, regulatory policy and director, U.S. post-market regulatory affairs at Philip Morris International, urged regulators to balance the desire to discourage underage uptake with the need to help adult smokers to move away from cigarettes.

 

“The reality is that the flavors that are liked by adults are almost identical to the flavors liked by youth,” Kozarewicz said. “So, there is a problem: tobacco harm reduction is all about successful transition from combustible cigarettes to better alternatives. We need flavors then to facilitate the switch, and we cannot base the policy on assumption that blueberry flavors are just a youth appealing flavor.” Kozarewicz called for more high-quality risk-assessments examining who is using a product and why. “With this, I believe we can have successful regulatory policies.”

 

Tobacco Giants Speak on THR at GFN: Calling for Regulatory Reform Aligned with Scientific Understanding
Piotr Kozarewicz (far right) during a panel discussion debating the role of flavors in nicotine products | Photo: Taco Tuinstra

 

 

Sharing Science

 

Keenly aware that credible research is vital to the success of THR, the GFN featured multiple “Science Labs,” providing participants with an opportunity to present their latest studies and discuss the results. Japan Tobacco International (JTI) shared new insights into the association between the use of heated tobacco products (HTPs) and the incidence of respiratory symptoms.

 

With the growing popularity of HTPs worldwide, and especially in Japan, interest has grown into the potential health effects of this relatively new product. However, because most HTP users are (former) smokers, it’s impossible to properly assess health impacts without considering users’ smoking history.

 

While JTI found a dose-response relationship between total incidence and amount of daily HTP use, its study results suggest that this relationship was largely due to users’ prior smoking history. The company’s research also revealed that the THR potential of HTPs is comparable across brands, suggesting that all heating products can help smokers reduce their risk.

 

2Firsts has been a media partner of the Global Forum on Nicotine (GFN) for three consecutive years.


 

You're welcome to submit articles, request interviews, or share your comments with 2Firsts. Please contact us at: info@2firsts.com, or reach out to 2Firsts CEO Alan Zhao on LinkedIn.

Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands (TPB) reported third-quarter 2026 Modern Oral net sales of $74.4 million on November 9, up 102.9% year over year and representing 49.2% of consolidated net sales. Total company net sales rose 27.0% to $151.1 million, while net income attributable to TPB declined 81.4% to $3.93 million. The company is expanding the US retail presence of its FRE and ALP nicotine pouch brands and expects its Modern Oral chain-store footprint to grow by more than 70% during 2026. Selling, general and administrative expenses increased 69.1% to $75.3 million, while PMTA-related expenses reached approximately $3.15 million and manufacturing start-up costs totaled about $593,000. ALP plans to open a branded pop-up in New York City's SoHo neighborhood on November 13, alongside a marketing campaign extending into January 2027. TPB owns 50% of ALP but consolidates the venture in its financial statements.
company
Nov.11
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana's Alcohol and Tobacco Commission (ATC) ordered tobacco certificate holders in September to remove certain vaping products marketed under Elf Bar, Lost Mary, MR FOG, iJOY and other brands from inventory under the state's foreign-adversary product law. The agency later listed 257 MR FOG products and 77 Lost Mary product entries as lawful for sale. The Lost Mary revision expressly stated that compliance evidence had been received for 20 additional products. 2Firsts compliance expert Kurt said potential filings could include e-liquid and ingredient-origin records, U.S. nicotine-analog supply-chain documentation and FDA premarket application status.
Regulations
Oct.08
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Swedish nicotine pouch brand Kelly White is building its strategy around adult female consumers. Founder and CEO Sophia Wilsby told 2Firsts that women accounted for around 70% of the brand’s repeat customers on HAYPP in Sweden in 2025. The interview explores female consumer segmentation, product and design differentiation, gender stereotypes, packaging regulation, and how independent brands can compete with global players such as ZYN and VELO while considering funding, partnerships and future ownership options.
Business
Sep.24